PT2114395E - Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações - Google Patents

Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações Download PDF

Info

Publication number
PT2114395E
PT2114395E PT78700119T PT07870011T PT2114395E PT 2114395 E PT2114395 E PT 2114395E PT 78700119 T PT78700119 T PT 78700119T PT 07870011 T PT07870011 T PT 07870011T PT 2114395 E PT2114395 E PT 2114395E
Authority
PT
Portugal
Prior art keywords
ophthalmic
oligomers
amphiphilic polymers
otic compositions
facially amphiphilic
Prior art date
Application number
PT78700119T
Other languages
English (en)
Portuguese (pt)
Inventor
Richard W Scott
Original Assignee
Cellceutix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellceutix Corp filed Critical Cellceutix Corp
Publication of PT2114395E publication Critical patent/PT2114395E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT78700119T 2006-12-29 2007-12-28 Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações PT2114395E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88280006P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
PT2114395E true PT2114395E (pt) 2015-07-07

Family

ID=39589209

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78700119T PT2114395E (pt) 2006-12-29 2007-12-28 Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações

Country Status (12)

Country Link
US (5) US20090092574A1 (enExample)
EP (1) EP2114395B1 (enExample)
JP (2) JP5512279B2 (enExample)
CN (3) CN102600163B (enExample)
AU (1) AU2007339790B2 (enExample)
CA (1) CA2674080C (enExample)
DK (1) DK2114395T3 (enExample)
ES (1) ES2538479T3 (enExample)
HU (1) HUE025868T2 (enExample)
PL (1) PL2114395T3 (enExample)
PT (1) PT2114395E (enExample)
WO (1) WO2008083256A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
CN102164892A (zh) 2008-07-28 2011-08-24 波利梅伊公司 抗疟疾化合物
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
ITTO20090131A1 (it) * 2009-02-24 2010-08-25 Liofarmaceutici Srl Composizioni oftalmiche contenenti teicoplanina
US20120258141A9 (en) * 2010-07-07 2012-10-11 University Of Medicine And Dentistry Of New Jersey Methods Of Immune Modulation
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
RU2606128C2 (ru) 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
TW202126313A (zh) * 2011-09-16 2021-07-16 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
AU2013209622A1 (en) * 2012-01-18 2014-09-11 Cellceutix Corporation Compounds and methods for treating Candidiasis and Aspergillus infections
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
CN108350395A (zh) 2015-09-03 2018-07-31 杜兰教育基金委员会 多用途消毒和灭菌溶液的组合物和方法
BR112018077281A2 (pt) * 2016-07-01 2019-04-02 Boulos & Cooper Pharmaceuticals Pty Ltd novos antibióticos
IT201900000561A1 (it) * 2019-01-14 2020-07-14 Medivis S R L Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
AU2022218993A1 (en) 2021-02-10 2023-08-03 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
IL311534A (en) 2021-09-22 2024-05-01 Iolyx Therapeutics Inc Methods of treating ocular inflammatory diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (enExample) 1972-11-30 1975-04-07 Pharmacia Ab
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4559343A (en) 1982-09-07 1985-12-17 Alcon Laboratories, Inc. Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents
US5223492A (en) 1987-10-27 1993-06-29 Nasraoui Nejib M Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them
US5190927A (en) 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
CA2128612C (en) * 1992-01-23 1999-06-15 Mamoru Tomita Antimicrobial agents and method for treating products therewith
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1996006581A1 (en) 1994-08-30 1996-03-07 R.P. Scherer Limited Ocular treatment device
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6025326A (en) 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) * 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
JP2003523927A (ja) * 1998-08-20 2003-08-12 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ジカチオンジベンゾフランおよびジベンゾチオフェン化合物並びにその使用法
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
JP2004525865A (ja) * 2000-11-08 2004-08-26 バイオ−コンセプト・ラボラトリーズ 過酸化物源およびカチオン性ポリマー防腐剤を含有する改良した眼科用およびコンタクトレンズ用溶液
BR0206734A (pt) 2001-01-18 2004-03-02 Genzyme Corp Polìmeros de ioneno e seu uso como agentes antimicrobianos
CA2789997A1 (en) * 2001-03-08 2002-12-19 William F. Degrado Facially amphiphilic polymers an anti-infective agents
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AU2002341566A1 (en) 2001-08-16 2003-04-01 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
WO2003100701A1 (en) * 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
US8234074B2 (en) * 2002-06-13 2012-07-31 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembrances using coarse grain models
AU2003291087A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
EP2471525A3 (en) 2003-03-17 2012-12-12 The Trustees Of The University Of Pennsylvania Facially amphiphllic polymers and oligomers and uses thereof
AU2003249114A1 (en) 2003-03-20 2004-10-11 Shiseido International France Cosmetic composition
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
TWI388280B (zh) * 2004-01-23 2013-03-11 Univ Pennsylvania 面上兩性之聚芳基和聚芳炔基聚合物與寡聚物及其用途
CN102653515A (zh) 2004-06-15 2012-09-05 宝利麦迪克斯股份有限公司 聚阳离子化合物及其用途
WO2006132647A2 (en) * 2004-07-23 2006-12-14 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
CA2599205A1 (en) * 2005-02-25 2006-09-08 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
EP1704860B1 (en) 2005-03-24 2010-10-27 Rottapharm S.P.A. Benzamidine derivatives for treatment and prevention of mucositis
AU2006244080C1 (en) 2005-05-10 2012-02-02 The University Of Chicago Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
US7951829B2 (en) 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) * 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
CN102164892A (zh) 2008-07-28 2011-08-24 波利梅伊公司 抗疟疾化合物
US8278309B2 (en) 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
BRPI0922947A2 (pt) 2008-12-10 2015-08-25 Polymedix Inc Métodos para inibir o crescimento de uma espécie de mycobacterium, e para tratar um animal tendo uma infecção de mycobacterium, e, composto.
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP2013516470A (ja) * 2010-01-07 2013-05-13 ポリメディックス・インコーポレーテッド 抗ヘパリン化合物
TW201208677A (en) 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
RU2606128C2 (ru) 2011-05-16 2017-01-10 Селлсьютикс Корпорейшн Соединения для применения в лечении мукозита
AU2013209622A1 (en) 2012-01-18 2014-09-11 Cellceutix Corporation Compounds and methods for treating Candidiasis and Aspergillus infections
WO2014093225A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Polycyclic compounds and methods of making and using the same
WO2014093231A2 (en) 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
CA2912728C (en) 2013-05-28 2021-04-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Also Published As

Publication number Publication date
ES2538479T3 (es) 2015-06-22
WO2008083256A2 (en) 2008-07-10
CA2674080C (en) 2016-08-09
EP2114395A4 (en) 2010-12-15
US10166232B2 (en) 2019-01-01
CA2674080A1 (en) 2008-07-10
AU2007339790B2 (en) 2013-07-18
JP5512279B2 (ja) 2014-06-04
US20160228435A1 (en) 2016-08-11
PL2114395T3 (pl) 2015-08-31
WO2008083256A3 (en) 2008-12-24
US20090092574A1 (en) 2009-04-09
US20210093636A1 (en) 2021-04-01
JP2010514798A (ja) 2010-05-06
DK2114395T3 (en) 2015-06-08
CN102600163B (zh) 2014-10-01
EP2114395B1 (en) 2015-03-04
AU2007339790A1 (en) 2008-07-10
EP2114395A2 (en) 2009-11-11
US9192623B2 (en) 2015-11-24
JP2014139219A (ja) 2014-07-31
US20190314370A1 (en) 2019-10-17
CN101631543A (zh) 2010-01-20
JP5745666B2 (ja) 2015-07-08
CN102600163A (zh) 2012-07-25
CN102342941A (zh) 2012-02-08
US20130065818A1 (en) 2013-03-14
CN101631543B (zh) 2011-12-07
HUE025868T2 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PT2114395E (pt) Composições oftálmicas e auriculares de polímeros e oligómeros facialmente anfifílicos e as suas utilizações
ZA200901386B (en) Masterbatch and polymer composition
GB0911139D0 (en) Directly photodefinable polymer compositions and methods thereof
HUE038560T2 (hu) Polimerek és készítményeik molekulatömeg-eloszlásának szabályzására vonatkozó eljárások
IL252421B (en) Preparations containing solid dispersions and their uses
EP2128196A4 (en) POLYMERIC COMPOSITION AND APPLICATION THEREOF
DK2139466T3 (en) Magnesium Compositions and Uses Thereof
ZA201008169B (en) Compositions and methods comprising variant microbial proteases
EP2134351A4 (en) METHODS AND COMPOSITIONS USED FOR PROLONGED CHROMIUM RELEASE
EP1848410A4 (en) COMPOSITIONS FOR DISPENSING POLYMER PARTICLES AND APPLICATION METHOD THEREFOR
AU2007291030A8 (en) Novel compositions and methods
IL179296A0 (en) Amphiphilic polymer compositions and their use
GB0622399D0 (en) Novel compositions and uses thereof
EP2231781A4 (en) HARDENING COMPOSITION AND HARDENING PRODUCT MADE THEREFOR
EP2207819B8 (en) Anti-microbial polymers and their compositions
GB0715428D0 (en) Compositions and uses thereof
ZA201103500B (en) New polymers and use thereof in preparation of high impact polymeric compositions
GB0701170D0 (en) Compositions and uses thereof
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0701171D0 (en) Compositions and uses thereof
PL2128112T3 (pl) Cząsteczkowe kompozycje odpowietrzające i sposoby ich stosowania
GB0622400D0 (en) Novel compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
AU2008903576A0 (en) Anti-Microbial Polymers and Their Compositions